Abstract: The present invention relates generally to the identification of the products of gene expression in cancerous tissue or other tissue associated with an aberrant medical condition. Identification of such expression products enables the development of a range of diagnostic and therapeutic agents. In one embodiment of the present invention, a gene is differentially or preferentially expressed in cancerous tissue relative to normal tissue. Identification of the expression product of the gene and of the gene itself provides a means of developing diagnostic and therapeutic agents for the treatment, prophylaxis, and diagnosis of the cancerous condition in which the gene is differentially or preferentially expressed.

Abstract: The present invention relates generally to molecules derived from a Mycobacterium species and recombinant, synthetic, derivative, homologue and analogue forms of said molecules. The molecules of the present invention are useful in diagnostic assays for Mycobacterium in biological and environmental samples. The present invention is particularly directed to molecules derived from Mycobacterium tuberculosis and related organisms and even more particularly to recombinant forms of these molecules or synthetic, derivative, homologue or analogue forms thereof and their use in diagnostic and therapeutic protocols for tuberculosis or other disease conditions associated with M. tuberculosis or related organisms.

Abstract: The present invention relates generally to the identification of the products of gene expression in cancerous tissue or other tissue associated with an aberrant medical condition. Identification of such expression products enables the development of a range of diagnostic and therapeutic agents. In one embodiment of the present invention, a gene is differentially or preferentially expressed in cancerous tissue relative to normal tissue. Identification of the expression product of the gene and of the gene itself provides a means of developing diagnostic and therapeutic agents for the treatment, prophylaxis, and diagnosis of the cancerous condition in which the gene is differentially or preferentially expressed.

Abstract: Peptide antigens derived from the dengue virus type-2 glycoprotein NS1 are provided. The peptide antigens are specifically immunoreactive with sera from individuals infected with the dengue virus. The antigens are useful as diagnostic tools in determining whether an individual has been or is infected with dengue virus, and for discriminating between infection with dengue virus and infection with related flaviviruses. The antigens are also useful in vaccine compositions for immunizing individuals against infection with the dengue virus.

Abstract: A method for producing an improved solid phase antigenic reagent useful in an immunoassay for detecting antibodies specific for a virus, such as the human immunodeficiency virus, is disclosed which comprising the addition to a natural viral lysate a synthetic or recombinant viral protein or peptide. Also provided is an improved immunoassay utilizing the solid phase antigenic reagent.